More tools:Markets·Screener·Research Chat

ABBVIE INC. (ABBV) Financial Statements

ABBVIE INC.
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG0025Y4RZ3
XNYS · usd
244.78▼ 3.22 (-1.30%)
As of 2026-07-14
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)$61.2B
Net Income (TTM)$3.6B
EBITDA
Diluted EPS (TTM)
EBITDA Margin38.2%
Net Debt
Trading Information
Previous Close248.00
Day's Range243.19 – 246.42
52-Week Range184.63 – 261.64
Volume5.22M
Avg Volume7.52M
Share Statistics
Shares Outstanding1.8B
Employees57.0K
ExchangeXNYS
Listed2012-12-10

Key questions about ABBVIE INC. (ABBV)

What is ABBVIE INC.'s Market Cap?
ABBVIE INC.'s Market Cap is $432.5B, based on as-reported figures from SEC (XBRL) filings.
What is ABBVIE INC.'s Enterprise Value?
ABBVIE INC.'s Enterprise Value is $506.0B, based on as-reported figures from SEC (XBRL) filings.
What is ABBVIE INC.'s Trailing P/E?
ABBVIE INC.'s Trailing P/E is 119.0×, based on as-reported figures from SEC (XBRL) filings.
What is ABBVIE INC.'s Price / Sales?
ABBVIE INC.'s Price / Sales is 7.1×, based on as-reported figures from SEC (XBRL) filings.
What is ABBVIE INC.'s EV / Revenue?
ABBVIE INC.'s EV / Revenue is 8.3×, based on as-reported figures from SEC (XBRL) filings.
What is ABBVIE INC.'s EV / EBITDA?
ABBVIE INC.'s EV / EBITDA is 21.7×, based on as-reported figures from SEC (XBRL) filings.
What is ABBVIE INC.'s Revenue (TTM)?
ABBVIE INC.'s Revenue (TTM) is $61.2B, based on as-reported figures from SEC (XBRL) filings.
What is ABBVIE INC.'s Net Income (TTM)?
ABBVIE INC.'s Net Income (TTM) is $3.6B, based on as-reported figures from SEC (XBRL) filings.
What is ABBVIE INC.'s EBITDA?
ABBVIE INC.'s EBITDA is $23.4B, based on as-reported figures from SEC (XBRL) filings.
What is ABBVIE INC.'s Diluted EPS (TTM)?
ABBVIE INC.'s Diluted EPS (TTM) is 2.06, based on as-reported figures from SEC (XBRL) filings.
Loading Income Statement…
Showing the most recent year. Subscribe for full statement history.
Income Statement(in millions of USD, except per-share data)
Source: Akyla.ai
Line ItemMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022
Net revenues
YoY growth+12.4%+10.0%+9.1%+6.6%
Cost of products sold
Selling, general and administrative
Research and development
Acquired IPR&D and milestones
Total operating costs and expenses
% of revenue73.4%72.7%87.9%68.3%
Income (loss) from operations
% of revenue26.6%27.3%12.1%31.7%
Interest expense, net
Other expense, net
Income (loss) before income taxes
Income tax expense (benefit)
Net earnings
% of revenue4.6%10.9%1.2%6.1%
Net earnings attributable to noncontrolling interest
Net earnings attributable to AbbVie Inc.
% of revenue4.6%10.9%1.2%6.1%
Basic earnings per share attributable to AbbVie Inc.
Diluted earnings per share attributable to AbbVie Inc.
Weighted-average basic shares outstanding
Weighted-average diluted shares outstanding